Pfizer (NYSE:PFE) Trading Down 2.6% – Here’s What Happened

Pfizer Inc. (NYSE:PFE)’s share price dropped 2.6% during mid-day trading on Thursday . The company traded as low as $24.94 and last traded at $25.2550. Approximately 119,368,447 shares changed hands during trading, an increase of 188% from the average session volume of 41,483,633 shares. The stock had previously closed at $25.92.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reiterated its full-year 2026 guidance, signaling that management does not expect the CFO transition to disrupt near-term financial plans. Pfizer Reaffirms 2026 Outlook Amid CFO Transition
• Neutral Sentiment: The company appointed Senior Vice President Cecile Guegan as interim CFO while it conducts a search for a permanent replacement, suggesting the transition is being managed in an orderly way. Pfizer Announces Chief Financial Officer Transition
• Neutral Sentiment: Analysts and market commentary also pointed to broader skepticism about Pfizer’s near-term growth catalysts, including concerns about pipeline timing and longer-term patent-expiration pressure. Pfizer Slides as Investors Appear to Reassess Near-Term Growth Catalysts
• Negative Sentiment: Investors appear concerned that Dave Denton’s departure creates uncertainty at the top of Pfizer’s finance organization, especially as the company works through major pipeline investment decisions and ongoing restructuring efforts. Pfizer CFO Dave Denton to step down, leave company in August

Analysts Set New Price Targets

A number of brokerages recently weighed in on PFE. Bank of America dropped their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Pfizer in a report on Monday, June 1st. Barclays started coverage on shares of Pfizer in a report on Thursday, February 19th. They set an “underweight” rating and a $25.00 price target on the stock. Zacks Research raised shares of Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. Finally, Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective on the stock in a research report on Monday, March 2nd. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and a consensus price target of $28.82.

Pfizer Stock Performance

The firm’s fifty day moving average is $26.30 and its 200 day moving average is $26.34. The firm has a market capitalization of $143.94 billion, a price-to-earnings ratio of 19.28 and a beta of 0.34. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm’s revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts predict that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, June 12th. Shareholders of record on Friday, May 8th were issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.8%. The ex-dividend date was Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Institutional Trading of Pfizer

Institutional investors and hedge funds have recently made changes to their positions in the stock. Brighton Jones LLC boosted its holdings in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after buying an additional 618,117 shares during the period. Revolve Wealth Partners LLC raised its holdings in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 2,087 shares during the period. United Bank lifted its position in Pfizer by 12.4% during the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after acquiring an additional 6,415 shares during the last quarter. Sei Investments Co. boosted its holdings in Pfizer by 31.5% during the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock valued at $63,889,000 after acquiring an additional 631,523 shares during the period. Finally, HUB Investment Partners LLC boosted its holdings in Pfizer by 45.3% during the second quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock valued at $2,480,000 after acquiring an additional 31,896 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.